Multiple myeloma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BCMA 132
• CD38 22
• GPRC5D 35
• CD19 31
• TP53 0
• STAT3 0
• CXCR4 4
• MYC 0
• BCL-2 2
• PI3K 1
• mTOR 0
• IL-6 0
• STING 0
• BRAF 2
• CD47 1
• HDAC 0
• AKT 0
• PD-1 1
• PD-L1 1
• CD20 3
• GLP-1 0
• JAK 0
• PTEN 0
• SGLT2 0
• AMPK 0
• B7-H3 0
• NRAS 1
• TIGIT 0
• CTLA-4 1
• ERK 0
• EZH2 0
• FTO 0
• IL-15 3
• JNK 0
• KRAS 1
• MAPK 0
• RAS 0
• CD22 2
• CD33 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• LAG-3 0
• MDM2 0
• METTL3 0
• NRF2 0
• BRCA1 0
• BRD4 0
• BTK 1
• CD123 1
• CD30 0
• CDK4/6 0
• GPX4 0
• HER2 0
• HIF-1 0
• HSP90 0
• MEK 0
• MET 0
• MUC1 0
• NTRK 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 74+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

  NCT04579523· Fred Hutchinson Cancer Center· Updated 11 Sept 2026

  “Study withdrawn before opening to accrual.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma

  NCT05461209· Janssen Research & Development, LLC· Updated 15 Aug 2025

  “Business Decision”Registry text, quoted unchanged. Source

• Terminated

  CART-38 in Adult AML and MM Patients

  NCT05442580· University of Pennsylvania· Updated 26 Jun 2025

  “Administrative decision”Registry text, quoted unchanged. Source

• Terminated

  Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

  NCT05908396· IGM Biosciences, Inc.· Updated 1 Aug 2024

  “Company Decision”Registry text, quoted unchanged. Source

• Withdrawn

  Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

  NCT04466475· Fred Hutchinson Cancer Center· Updated 31 Jan 2024

  “NIH terminated funding. Study was closed before any participants were enrolled.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Regeneron Pharmaceuticals· Source

• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05572515· Janssen Research & Development, LLC· Source

• A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07266441· Janssen Research & Development, LLC· Source

• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

  NCT06208150· Janssen Research & Development, LLC· Source

• A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Janssen Research & Development, LLC· Source

• A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

  NCT07030517· Johnson & Johnson Private Limited· Source

• A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT06356571· Sanofi· Source

• A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments

  NCT07881835· Pfizer· Source

• A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma

  2025-523815-12-00· Janssen Cilag International· Source

• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

  NCT04649359· Pfizer· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 3
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 8
• Gene Expression Profiling 44
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Exome Sequencing 3
• Proteomics 15
• Metabolomics 10
• Mass Spectrometry 7
• Flow Cytometry 48
• Immunohistochemistry 11
• Liquid Biopsy 2
• Circulating Tumor DNA 2
• Xenograft Model Antitumor Assays 78
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 26
• Machine Learning 16
• Deep Learning 6
• Cohort Studies 32
• Genome-Wide Association Study 7

See which targets of this disease your abstract mentions, and go to the people working on them.